For healthcare professionals only

Letters Breast cancer screening trial

Time to halt an out of control trial with ineffective oversight

BMJ 2014; 349 doi: (Published 16 September 2014) Cite this as: BMJ 2014;349:g5601
  1. Susan Bewley, professor of complex obstetrics1,
  2. Les Rose, retired clinical research scientist2,
  3. Peter Gøtzsche, director3,
  4. Mitzi Blennerhassett, medical writer/author4,
  5. David Colquhoun, professor of pharmacology5,
  6. Miriam Pryke, PhD student6,
  7. Gillian Tindall, writer7,
  8. Alain Braillon, senior consultant8,
  9. Caroline Richmond, medical journalist9,
  10. John Illman, medical journalist9,
  11. James May, general practitioner9
  1. 1Women’s Health Academic Centre, c/o 10th floor St Thomas’ Hospital, London SEI 7EH, UK
  2. 2Salisbury, UK
  3. 3Nordic Cochrane Centre, Copenhagen, Denmark
  4. 4York, UK
  5. 5University College London, London, UK
  6. 6King’s College London, London, UK
  7. 7Cambridge, UK
  8. 8Alcohol Treatment Unit, University Hospital, Amiens, France
  9. 9London, UK
  1. susan.bewley{at}

Detailed scientific and ethical concerns have repeatedly been raised about the less than robust mammography screening age extension trial.1 2 3 The chief investigator is not medically or scientifically qualified, encourages contamination, ignores questions or obfuscates, and both runs the national programme and chairs the (non-independent) trial steering committee.

The eight page study protocol,4 produced only after repeated freedom of information requests, contains two references and has …

View Full Text

Log in

Log in through your institution


* For online subscription